VIGL — Vigil Neuroscience Share News
0.000.00%
Last trade - 00:00- $375.71m
- $288.60m
Brief: Vigil Neuroscience Q3 EPS USD -0.47 Vs. IBES Estimate USD -0.54
U.S. STOCKS ON THE MOVE- Teladoc Health, Veritex, New York Community Bancorp
U.S. STOCKS ON THE MOVE- AppLovin, Regal Rexnord, Talkspace
U.S. STOCKS ON THE MOVE-GE Vernova, Dell, Super Micro Computer
U.S. STOCKS ON THE MOVE-Intel, ANI Pharmaceuticals, New York Community Bancorp
Vigil Neuroscience rises as FDA lifts partial hold on Alzheimer’s disease trial
Brief: Vigil Neuroscience Q2 EPS USD -0.52 Vs. IBES Estimate USD -0.55
Brief: Vigil Neuroscience Announces Interim Data From Phase 1 Trial Evaluating Vg-3927
Brief: Vigil Neuroscience Announces $40 Million Strategic Investment From Sanofi
Brief: Vigil Neuroscience Q1 EPS USD -0.5 Vs. IBES Estimate USD -0.61
Brief: Vigil Neuroscience Q4 EPS USD -0.57
Brief: Vigil Neuroscience - Extends Projected Cash Runway Into Second Half Of 2025
U.S. STOCKS ON THE MOVE-Primerica, Canopy Growth, Applied Materials
U.S. STOCKS ON THE MOVE-Copart, Expedia, Chevron
Brief: Vigil Neuroscience Expects To Report Phase 2 Ignite Results From All Patients In 20 Mg/KG And 40 Mg/KG Cohorts At 6 Months In Q3 Of 2024
Brief: Vigil Neuroscience Q3 EPS USD -0.53
Outset Medical falls on 2023 revenue forecast cut
Brief: Vigil Neuroscience Inc Provided An Update On Company's Small Molecule Trem2 Agonist, Vg-3927
Brief: Vigil Neuroscience Receives Positive Opinion From European Medicines Agency On Orphan Drug Designation For VGL101 For The Treatment Of ALSP